Newsroom | 101979 results

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older...

PARIS--(BUSINESS WIRE)--Spotlight Medical, a Paris-based oncology diagnostics company, today announced that myStage Dx has received CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746). The milestone advances Spotlight Medical’s European commercialization strategy and enables implementation of myStage Dx with oncology centers, pathology laboratories and digital pathology partners. In ER+/HER2− early breast cancer, physicians increas...

SAN DIEGO & BERLIN--(BUSINESS WIRE)--Vividion announced that the first patient has been dosed in a Phase Ib combination clinical trial for VVD-214, an investigational oral WRN inhibitor....

PARIS & BOSTON--(BUSINESS WIRE)--  Bionyra Pharma se lance avec une levée de fonds de série A de 165 millions de dollars, sursouscrite, afin de faire progresser son portefeuille de produits en phase clinique, composé de produits biologiques de nouvelle génération destinés au traitement des maladies inflammatoires à médiation immunitaire Bionyra Pharma, une société biopharmaceutique au stade clinique qui développe des produits biologiques de nouvelle génération destinés au traitement des maladie...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan announced the closing of its initial public offering....

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, l'azienda che ha creato il sistema di istotripsia Edison® e le innovative piattaforma per la terapia con questa tecnica, oggi ha annunciato la chiusura di un nuovo round di finanziamento con la partecipazione di Reed Jobs and Yosemite, il cui obiettivo è “rendere il cancro non-letale nel corso della nostra vita”, assieme a diversi nuovi investitori. Gli ulteriori termini del finanziamento non sono stati divulgati. Il finanziamento giunge in un momento...

明尼亞波里斯--(BUSINESS WIRE)--(美國商業資訊)-- Edison®組織摧毀術系統及新型組織摧毀術治療平台的開發商HistoSonics今日宣布完成新一輪募資，Reed Jobs和Yosemite參與了本輪投資，其目標是「在我們有生之年讓癌症不再致命」。此外，還有幾家新的策略投資人也參與了此次募資。具體的募資條款未予揭露。 此次募資正值HistoSonics發展動力強勁之際。公司正在全球持續擴大組織摧毀術在肝臟腫瘤治療中的臨床應用，並迅速推進其非侵入性平台在實質腫瘤領域的其他應用。 HistoSonics董事長兼執行長Mike Blue表示：「打造一家劃時代的公司需要合作夥伴，而合作夥伴的作用遠不止提供資金。此次募資進一步引進了認同我們的使命、深知未來機會巨大，並與我們一樣致力於為病患、醫生和股東創造持久價值的策略投資人。」 在過去的一年裡，HistoSonics在消除肝臟腫瘤（包括轉移性腫瘤）方面加快了商業化和臨床進展，越來越多的醫生開始採用該療法，頂尖的學術醫療中心和醫療系統對該技術的使用率也在不斷增加。此外，公司近期向美國食品藥物管理局(FDA)遞交了De No...

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的开发商HistoSonics今日宣布完成新一轮融资，Reed Jobs和Yosemite参与了本轮投资，其目标是“在我们有生之年让癌症不再致命”。此外，还有几家新的战略投资者也参与了此次融资。具体的融资条款未予披露。 此次融资正值HistoSonics发展势头强劲之际。公司正在全球范围内持续扩大组织摧毁术在肝脏肿瘤治疗中的临床应用，并迅速推进其无创平台在实体瘤领域的其他应用。 HistoSonics董事长兼首席执行官Mike Blue表示：“打造一家划时代的公司需要合作伙伴，而合作伙伴的作用远不止提供资金。此次融资进一步引入了认同我们的使命、深知未来机遇巨大，并与我们一样致力于为患者、医生和股东创造持久价值的战略投资者。” 在过去的一年里，HistoSonics在消除肝脏肿瘤（包括转移性肿瘤）方面加速了商业化和临床进展，越来越多的医生开始采用该疗法，顶尖的学术医疗中心和医疗系统对该技术的使用率也在不断增加。此外，公司近期向美国食品药品监督管理局(FDA)提交了D...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvo...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, de ontwikkelaar van het Edison® Histotripsy System en nieuwe platformen voor histotripsietherapie, maakte vandaag de afronding bekend van een nieuwe financieringsronde met deelname van Reed Jobs en Yosemite, die ernaar streven om “kanker niet-dodelijk in onze levensloop te maken”, samen met verschillende nieuwe strategische investeerders. Er werden geen andere financiële voorwaarden bekendgemaakt. Deze financiering komt op een belangrijk momentum voor...